Atea Pharmaceuticals Inc Stock

$2.89

2.69%

Nasdaq, Apr 21, 08:45 pm CET

ISIN

US04683R1068

Symbol

AVIR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Atea Pharmaceuticals Inc Stock price

$2.97

-27.37 90.21% 5Y

Nasdaq, Closing price Thu, Apr 17 2025

-0.03 1.00%

ISIN

US04683R1068

Symbol

AVIR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$254.01m
Enterprise Value	$-199.07m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	1.47
P/B ratio (TTM) P/B ratio	0.57
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-192.95m
Free Cash Flow (TTM) Free Cash Flow	$-135.50m
Cash position	$454.72m
EPS (TTM) EPS	$-2.00
P/E forward	negative
Short interest	4.92%

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Get Started for Free Today

Atea Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Atea Pharmaceuticals Inc forecast:

1x Buy

33%

1x Hold

33%

1x Sell

33%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Atea Pharmaceuticals Inc forecast:

Buy

33%

Hold

33%

Sell

33%

Analyst Estimates with Stock Price Targets

Financial data from Atea Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.42 0.42	0% 0% -
Gross Profit	-0.42 -0.42	0% 0% -
- Selling and Administrative Expenses	48 48	2% 2% -
- Research and Development Expense	144 144	26% 26% -
EBITDA	-193 -193	18% 18% -
- Depreciation and Amortization	0.42 0.42	0% 0% -
EBIT (Operating Income) EBIT	-193 -193	18% 18% -
Net Profit	-168 -168	24% 24% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Atea Pharmaceuticals Inc Stock News

Neutral

GlobeNewsWire

●

4 days ago

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D.

Neutral

GlobeNewsWire

●

12 days ago

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect

Neutral

GlobeNewsWire

●

21 days ago

Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination

States Change in Board Composition Sorely Needed Expresses Support for Radoff-JEC Group Nominees STAMFORD, Texas, March 31, 2025 (GLOBE NEWSWIRE) -- Driver Management Company LLC (“Driver”) today delivered a letter to Atea Pharmaceuticals, Inc. (“Atea” or the “Company”) withdrawing a notice of nomination delivered to the Company on March 19, 2025 in order not to compete against the highly quali...

More Atea Pharmaceuticals Inc News

Company Profile

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Head office	United States
CEO	Jean-Pierre Sommadossi
Employees	56
Founded	2012
Website	www.ateapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now